Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

NCT02974647 · clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
83
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators